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Abstract
Study Objective—Our aim was to assess incidence and risk factors for pelvic pain after pelvic 
mesh implantation.
Design—Retrospective study (Canadian Task Force classification II-2).
Setting—Single university hospital.
Patients—Women who have undergone surgery with pelvic mesh implant for treatment of pelvic 
floor disorders including prolapse and incontinence.
Interventions—Telephone interviews to assess pain, sexual function, and general health.
Measurements and Main Results—Pain was measured by the McGill Short-Form Pain 
Questionnaire for somatic pain, Neuropathic Pain Symptom Inventory for neuropathic pain, 
Pennebaker Inventory of Limbic Languidness for somatization, and Female Sexual Function Index 
(FSFI) for sexual health and dyspareunia. General health was assessed with the 12-item Short-
Form Health Survey. Among 160 enrolled women, mean time since surgery was 20.8 ± 10.5 
months, mean age was 62.1 ± 11.2 years, 93.8% were white, 86.3% were postmenopausal, and 
3.1% were tobacco users. Types of mesh included midurethral sling for stress incontinence 
(78.8%), abdominal/robotic sacrocolpopexy (35.7%), transvaginal for prolapse (6.3%), and 
perirectal for fecal incontinence (1.9%), with 23.8% concomitant mesh implants for both prolapse 
and incontinence. Our main outcome, self-reported pelvic pain at least 1 year after surgery, was 
15.6%. Women reporting pain were younger, with fibromyalgia, worse physical health, higher 
somatization, and lower surgery satisfaction (all p < .05). Current pelvic pain correlated with early 
postoperative pelvic pain (p < .001), fibromyalgia (p = .002), worse physical health (p = .003), and 
somatization (p = .003). Sexual function was suboptimal (mean FSFI, 16.2 ± 12.1). Only 54.0% 
were sexually active, with 19.0% of those reporting dyspareunia.
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Conclusion—One in 6 women reported de novo pelvic pain after pelvic mesh implant surgery, 
with decreased sexual function. Risk factors included younger age, fibromyalgia, early 
postoperative pain, poorer physical health, and somatization. Understanding risk factors for pelvic 
pain after mesh implantation may improve patient selectionq.
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Pelvic mesh implant surgery is commonly used to treat pelvic organ prolapse (POP) and 
stress urinary incontinence (SUI) and less commonly used for fecal incontinence (FI). It is 
estimated that by age 80, 20% of US women will have undergone surgery for the treatment 
of POP and/or SUI [1]. There is no consensus as to whether surgical repair should be 
augmented with mesh and what type of mesh to use. In 2008 the US Food and Drug 
Administration (FDA) released a Safety Notification for the use of pelvic mesh, based on 
over 1000 reports of complications reported to the Manufacturer and User Device 
Experience database [2]. Complications with mesh implant surgery reported in the database 
include pelvic pain, vaginal scarring, mesh erosion or exposure, dyspareunia, infection, 
urinary problems, bowel/bladder/blood vessel perforation, and POP/SUI recurrence. In 2011 
the FDA released an updated Safety Communication based on a growing number of reported 
complications associated with mesh implant surgery [2]. These reports have led to 
considerable controversy regarding the use of mesh implants in pelvic surgery for POP and 
SUI.
A systemic review published in 2008 reported outcomes with mesh use in transvaginal POP 
repair [3]. The authors found weak evidence supporting mesh augmentation in the anterior 
vaginal compartment in terms of POP repair, but with higher rates of mesh-related 
complications. Mesh complications included bleeding (0–3%), visceral injury (1–4%), 
urinary infection (0–19%), graft erosion (0–30%), and fistula (1%). Data were insufficient 
regarding pelvic pain and sexual dysfunction. In 2015 another systematic review compared 
the use of abdominal mesh for sacrocolpopexy with native tissue vaginal repair [4]. 
Moderate quality evidence favored sacrocolpopexy over native tissue repair for successful 
surgical treatment of POP. However, complications were higher in the sacrocolpopexy 
group, including ileus or small bowel obstruction (2.7% vs .2%), mesh or suture 
complications (4.2% vs .4%), and thromboembolism (.6% vs .1%).
Although mesh augmentation can improve anatomic outcomes, it is associated with higher 
complication rates such as erosion, pain, and sexual dysfunction that can lead to reoperation 
[5–9]. The risk of reoperation for mesh complications in the mesh group must be weighed 
against the risk of reoperation for POP recurrence in the native tissue group [10–12]. 
Unfortunately, it is difficult to remove a mesh implant in its entirety. Although reoperation 
for mesh complications can usually address mesh erosion, it is less successful in treating 
pelvic pain related to mesh implants [13]. This may be due to underlying peripheral 
neuralgia as well as centrally mediated hypersensitization of neural pathways.
The incidence of persistent pain after pelvic surgery with mesh is not well understood. It is 
hypothesized that women with other pain syndromes may be at higher risk of developing 
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chronic pelvic pain after mesh implant surgery, but this has not been directly reported for 
this type of surgery. Literature in other types of gynecologic surgery has shown that baseline 
preoperative pain is a predictor of chronic postoperative pain after hysterectomy [14]. 
Similarly, a meta-analysis of patients undergoing total knee arthroplasty found that pain at 
other sites, catastrophizing, and depression were all predictors of chronic postoperative pain 
[15]. Thus, our primary objective was to determine the incidence of chronic pelvic pain after 
mesh implant surgery for the treatment of POP and/or SUI at least 1 year after surgery. Our 
secondary objective was to identify patient and surgical factors associated with the 
development of postoperative pelvic pain after pelvic mesh implant surgery.
Methods
After institutional review board approval, women were identified from a surgical databased 
who had undergone pelvic mesh implant surgery between July 2011 and April 2014 with an 
attending surgeon in the University of North Carolina at Chapel Hill Division of Female 
Pelvic Medicine and Reconstructive Surgery. STROBE guidelines were followed [16]. These 
women were contacted via telephone and offered study enrollment. Assessments were 
conducted over the telephone. Exclusion criteria were prior pelvic mesh surgery, repeat 
pelvic surgery after the index surgery (with or without mesh), baseline self-reported pelvic 
pain, or less than 1 year since index surgery. Concomitant native tissue repair was allowed. 
Although pre-existing pelvic pain was an exclusion, some subjects did report other baseline 
chronic pain states, including fibromyalgia, temporomandibular joint pain, arthritis, and 
chronic back pain. These diagnoses were elicited during subject interview and confirmed in 
the medical record. Mesh erosion was assessed by querying the medical record based for 
International Classification of Diseases, Ninth Revision (ICD-9) codes 629.31 and 629.32 
for the diagnosis of “erosion of mesh into pelvic and non-pelvic organs” and for cases of 
surgical mesh revision and also during subject interview.
Eligible women were those who had undergone mesh implant surgery with any of the 
following procedures: transvaginal midurethral mesh sling for SUI (designated by Current 
Procedural Terminology [CPT] code 57288), abdominal or robotic sacrocolpopexy mesh for 
POP (CPT codes 57280 and 57425), transvaginal mesh for POP (CPT code 57267), or 
transperineal perirectal mesh for FI (CPT code 57267). Subjects who underwent more than 1 
mesh implant (i.e., mesh for SUI and POP) were included. Multiple mesh implants involved 
2 subgroups: (1) transvaginal mesh implant for POP and transvaginal mesh sling for SUI or 
(2) sacrocolpopexy mesh implant for POP and transvaginal mesh sling for SUI. Specific 
mesh brands used for POP repair included Prolene (Ethicon, Somerville, NJ) mesh for 
abdominal sacrocolpopexy, IntePro (American Medical Systems, Minnetonka, MN) and 
Alyte (Bard Medical, Covington, GA) mesh for robotic sacrocolpopexy, Uphold (Boston 
Scientific, Marlborough, MA) mesh for transvaginal POP repair, and TOPAS (American 
Medical Systems) perirectal mesh for FI. Specific mesh brands used for transvaginal SUI 
repair included SPARC (American Medical Systems) pubovaginal sling, TVT-Exact 
(Ethicon) pubovaginal sling, and Monarch (American Medical Systems) transobturator 
sling. The electronic medical record was used to review the operative report for data 
including surgical technique, estimated blood loss, and any surgical complications.
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For our main outcome, current pelvic pain was defined by self-report of any level of pain 
between the umbilicus and groin present for ≥6 months and occurring on at least a weekly 
basis. Pain quality was measured using the McGill Short-Form Pain Questionnaire (MPQ) 
for somatic pain, the Neuropathic Pain Symptom Inventory (NPSI) for neuropathic pain, and 
the Pennebaker Inventory of Limbic Languidness (PILL) for somatization. The MPQ 
contains 11 verbal descriptors assessing sensory components of pain, 5 verbal descriptors 
assessing affective components of pain, and 1 verbal descriptor describing pain intensity 
[17]. The MPQ has been successfully used to quantify chronic pelvic pain after surgery [18]. 
Maximum score is 45 (33 on the Somatic subscale and 12 on the Affective subscale), with 
higher scores indicating worse somatic pain. The NPSI has been used to characterize 
neuropathic pain and to identify treatment responders and nonresponders [17–19]. It allows 
differentiation of subtypes of neuropathic pain, including burning pain, pressing pain, 
paroxysmal pain, evoked pain, and parasthesia pain. The highest possible score is 100, with 
higher scores indicating worse neuropathic pain. The PILL assesses somatization, which is 
the expression of psychological distress with physical symptoms [19]. Elevated PILL scores 
in pain patients are highly correlated with the number of tender muscle sites, pain sensitivity, 
and progression to chronicity. The maximum possible score is 216, with higher scores 
indicating higher levels of somatization. A score > 66 is considered to be above the average 
range, whereas a score > 84 is considered highly elevated.
Sexual health and dyspareunia were measured with the Female Sexual Function Index 
(FSFI) [20], a 19-item questionnaire that measures physiologic and affective aspects related 
to sexual arousal and sexual activity. It contains 6 subscales, including Desire, Arousal, 
Lubrication, Orgasm, Satisfaction, and Pain. Subjects who are not sexually active can still be 
fully evaluated with this tool. The FSFI has been used to reliably assess sexual dysfunction 
associated with pelvic pain [21], including chronic pelvic pain after pelvic mesh implant 
surgery [22]. The highest possible score is 36, with higher score indicating better sexual 
health. Dyspareunia was defined as a score of 2.8 or less on the FSFI Pain subscale 
(describing “moderate” or “severe” pain “most of the time” with intercourse).
General health was assessed with the 12-item Short-Form Health Survey (SF-12) Physical 
and Mental subscales. The SF-12 is a valid and reliable measure of mental and physical 
health status reflecting the values and preferences for health from the person’s perspective 
[23]. The SF-12 has been used to evaluate the impact of therapeutic strategies on quality of 
life in women with chronic pelvic pain [24]. The maximum possible score is 100 for each 
subscale, with scores greater than 50 indicating above-average health status and scores less 
than 50 indicating below-average health status. Finally, surgical satisfaction was assessed on 
a 10-point scale, with 0 being completely dissatisfied and 10 being completely satisfied. 
Demographic, medical, and surgical details were abstracted from electronic medical records. 
Postoperative pain was extracted from the medical record, specifically based on the 
documentation of continued pain at the 6-week postoperative visit, which is part of the 
standard assessment.
Statistical analysis was performed with IBM SPSS version 22.0 (IBM SPSS Inc., Chicago, 
IL). Pearson-χ2 test, Fisher’s exact test, and Student’s t test and Spearman correlation were 
performed where appropriate. A p < .05 was considered statistically significant.
Geller et al. Page 4
J Minim Invasive Gynecol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results
Of 558 eligible women who underwent mesh implant surgery between July 2011 and April 
2014, 398 either could not be reached (n = 342), were ineligible (n = 42), or declined (n = 
14), leaving 160 women, who were enrolled. No women reported repeat pelvic mesh surgery 
since the index surgery. Mean time since surgery was 21 months (Table 1). Most study 
participants were over age 60, white, and postmenopausal. Tobacco use was rare (1.9%), 
with an average of half a pack per day for current smokers. Mean stage of prolapse before 
surgery was stage II for anterior (mean POP Quantification [POP-Q] System point Ba, .4 
± 2.3), stage II for posterior (mean POP-Q System point Bp, −1.0 ± 2.1), and stage I for 
apical/uterine (mean POP-Q System point C, −3.3 ± 4.4). Concurrent hysterectomy was 
performed in 23.8% of women, with the majority as total vaginal (50.0%), followed by total 
robotic (34.2%), robotic supracervical (10.5%), total laparoscopic (2.6%), and total 
abdominal (2.6%).
Types of mesh implant included mesh sling for SUI (78.8%), abdominal or robotic 
sacrocolpopexy (35.7%), vaginal mesh for POP (6.3%), and perirectal mesh (1.9%). Types 
of slings used for the treatment of SUI included TVT-Exact (61.9%), Monarch TOT 
(18.3%), and SPARC (16.7%), with 2% not documented. Types of mesh used for 
sacrocolpopexy included Alyte (70.6%) and IntePro (11.8%) for robotic cases and Prolene 
(15.7%) for abdominal cases, with 12% not documented. All transvaginal mesh implants for 
the treatment of POP were performed with Uphold. All perirectal mesh implants for the 
treatment of FI were performed with Topas. Among all subjects, 23.8% had concomitant 
mesh implants for both POP and SUI. Table 1 displays the distribution of mesh by type for 2 
study groups, those reporting current pain and those not reporting current pain, 
distinguishing single implants for POP or SUI from double implants for both POP and SUI. 
The rate of reported mesh erosion was .6%.
Surgery satisfaction was high at 8.1 for the entire cohort. Physical health was slightly below 
average, with a mean SF-12 Physical subscale score of 48.5 ± 10.5. Mental health was 
slightly above average, with a mean SF-12 Mental subscale score of 53.7 ± 9.3. 
Somatization was within normal range, based on a PILL mean score of 46.1 ± 25.5. For all 
subjects sexual function was moderately poor, based on a mean FSFI score of 16.2 ± 12.1; 
54.0% of women were sexually active at the time of assessment, with 19.0% of those 
reporting dyspareunia.
Our primary outcome, the rate of current self-reported postoperative pelvic pain (as defined 
in Methods) at least 1 year after surgery, was 15.6%. We compared women reporting current 
postoperative pain with those denying current postoperative pelvic pain (Table 1). Women 
with current pelvic pain were younger (p = .02) and had a higher rate of fibromyalgia (p = .
007). There were no differences in other demographics, including mean time since surgery, 
body mass index, smoking status, concurrent hysterectomy, other chronic pain diagnoses, 
mesh location, number of mesh implants, or mesh erosion. Women who reported current 
pelvic pain also demonstrated differences in general health and pain perception compared 
with those without pelvic pain. Specifically, women reporting pelvic pain demonstrated 
poorer physical health (SF-12 Physical score), more somatization (PILL score), and lower 
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surgery satisfaction compared with women not reporting pelvic pain. Notably, there was no 
difference in the rate of sexual activity for women with and without pelvic pain (56.5% vs 
53.4%) with no difference in sexual function based on FSFI score (Table 2).
Our secondary objective was to identify specific patient characteristics and surgical factors 
associated with pelvic pain after pelvic mesh implant surgery. Current pelvic pain at least 1 
year after surgery was positively correlated with postoperative pelvic pain at the 6-week 
postoperative visit (rho = .8, p < .001) and with the presence of fibromyalgia (rho = .3, p = .
002). Pain was inversely correlated with age (rho = −.2, p = .02), SF-12 Physical score (rho 
= −.3, p = .003), and PILL score (rho = −.3, p = .003), that is, women reporting pelvic pain 
were younger, with poorer physical health and increased somatization. Binomial regression 
was also performed. When assessing the effects of age, fibromyalgia, physical health 
(SF-12), and somatization (PILL), only age retained a significant association with current 
pelvic pain (p = .034; odds ratio, .95).
Women who reported current pelvic pain completed 2 additional pain questionnaires: the 
MPQ to assess somatic pain and the NPSI to assess neuropathic pain (Table 2). The level of 
somatic pain was mild, based on mean MPQ score. The level of neuropathic pain was 
relatively low based on mean NPSI score. Mesh location did not predict who would develop 
postoperative pain. However, in women reporting pelvic pain, there were differences in pain 
quality based on mesh location. When assessing pain scores based on mesh location, the 
following scores were significantly different: NPSI total (p = .026), NPSI Evoked Pain 
subscale (p = .014), and NPSI Parasthesia subscale (p = .008) (Fig). The mesh location with 
the highest rates of neuropathic pain based on NPSI scores was perirectal, followed by 
double-mesh implant of transvaginal mesh for POP and SUI. Sacrocolpopexy alone and 
sacrocolpopexy in combination with the midurethral sling for SUI had comparatively lower 
levels of neuropathic pain. Use of the midurethral sling for SUI with no other mesh had the 
lowest level of neuropathic pain. Tukey post-hoc analysis did not identify a specific mesh 
location as having statistically different scores from the others. There were no subjects in the 
vaginal Uphold-alone group who reported current pelvic pain, and thus they did not 
complete the NPSI questionnaire. Therefore, this group was not included in this analysis.
To account for nonresponders, a post-hoc analysis was performed, which showed no 
differences in the types of surgeries performed in this group compared with the responder 
group. Although both groups had a mean age in the postmenopausal range, the 
nonresponders were slightly younger at 58.7 years compared with 62.1 years for the 
responders (p = .003). No other demographic differences were found between the 2 groups.
Discussion
One in 6 women reported de novo pelvic pain at least 1 year after pelvic mesh implant 
surgery, with decreased sexual function. Associated factors included younger age, 
fibromyalgia, persistent early postoperative pain, poorer physical health, and increased 
somatization. Mesh location did not predict postoperative pelvic pain. Rather, all types of 
mesh implants were associated with some degree of somatic and neuropathic pain in the 
group reporting pain. In terms of pain quality, perirectal and double vaginal mesh implant 
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had the highest rates of neuropathic pain, whereas sacrocolpopexy alone and sacrocolpopexy 
in combination with the midurethral sling for SUI had comparatively lower levels of 
neuropathic pain and vaginal sling for SUI had the lowest rates of neuropathic pain. Because 
subjects did not undergo a physical examination, we could not report on the nature of the 
reported pain in comparison with mesh location. However, in our clinical experience, pelvic 
pain after mesh implant is variable in presentation, is not typically limited to the actual site 
of mesh implant, but can be present throughout various sites within and beyond the pelvis. In 
addition, patients who experience hypersensitization and centralization of their pain often 
have generalized or paradoxical pain on exam. Thus, although the physical exam is 1 
element of the evaluation, a multimodal assessment is needed, including validated 
questionnaires and a thorough history of the timing of the onset of pelvic pain after mesh 
implant to diagnose, determine severity and causality, and create a tailored treatment plan.
The process by which pelvic pain develops after mesh implant surgery is likely 
multifactorial. The challenge lies not only in the lack of understanding of the etiology of 
pain development and predisposing risk factors but also in the lack of published data that 
directly measure pelvic pain after mesh implant surgery. Although some studies report on 
the incidence of dyspareunia, very few directly measure pain with validated instruments, 
making it difficult to fully grasp the scope and nature of the problem. Dyspareunia does not 
equate with pelvic pain, because many women with pelvic pain are not sexually active, and 
thus dyspareunia is not directly assessed. In our study the rate of pelvic pain was 15.6%, 
whereas the rate of dyspareunia was 19% among sexually active women. Interestingly, most 
women with dyspareunia did not report current pelvic pain (66.7% denied current pain vs 
33.3% reported current pain, p = .11). This may be because 46% of women were not 
sexually active and thus would not report dyspareunia. Another explanation is that women 
with dyspareunia did not consider it a criterion for pelvic pain. This highlights the 
importance of directly measuring pelvic pain rather than using dyspareunia as a proxy.
Miller et al [25] evaluated 5-year outcomes after transvaginal mesh placement using a 
Prolene mesh implant for the treatment of POP. They reported 3 patients (3.5%) with 
dyspareunia but did not directly measure pelvic pain. A Cochrane Systematic Review from 
2013 also had little data regarding pain after mesh implant surgery [26]. However, their 
finding that sacrocolpopexy had a lower rate of dyspareunia than vaginal sacrospinous 
ligament fixation is in line with our findings.
Foon et al [27] performed a systematic review of graft materials in anterior vaginal wall POP 
repair but found insufficient evidence regarding dyspareunia rates and did not comment on 
pelvic pain. Feiner et al [28] performed a systematic review of transvaginal mesh kits for the 
treatment of apical POP and found dyspareunia rates of 2% to 3%. This review is 1 of the 
few to directly report on pain, with rates of perineal, pelvic, or buttock pain ranging from 1% 
to 2%. Pain was not a measured with a validated instrument in the included studies, so the 
reported rates of pain may not be inclusive of all cases. In contrast, Weber et al [29] reported 
a 19% dyspareunia rate after posterior native tissue repair. Similarly, Pauls et al [30] 
reported a 25% rate of sexual dysfunction related to vaginal pain after vaginal surgery for 
POP and SUI The rates of dyspareunia and pain reported by Weber et al and Pauls et al are 
more similar to our reported rate of 15.6% for pain and 19.0% for dyspareunia.
Geller et al. Page 7
J Minim Invasive Gynecol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mesh erosion can also be a source of pelvic pain, and this has been more directly reported in 
the literature [9]. However, revision of mesh erosion may be performed for a variety of 
reasons, including dyspareunia, bleeding, and infection, and it is difficult to make any direct 
inferences as to the presence or absence of pain. Unfortunately, mesh erosion rates cannot be 
used as a proxy to identify the presence of pelvic pain after mesh implant surgery. The mesh 
erosion rate in our study was very low. This information was obtained by querying the 
medical record based on ICD-9 codes 629.31 and 629.32 for erosion of mesh into pelvic and 
nonpelvic organs and by checking for any cases of surgical mesh revision and interviewing 
the subjects. Based on the retrospective nature of the study, it is possible that not all cases 
were reported and thus not identified.
Strengths of the present study include the use of validated instruments to directly measure 
pain quality after mesh implant, general health, and sexual health, which allows for very 
specific assessments of different types of pain responses, including somatic and neuropathic 
pain, and somatization. In addition, inclusion of a wide variety mesh implant types allows 
for subanalysis of outcomes by mesh location. Finally, the study period spanned the time 
directly after the FDA Safety Warning of 2011, allowing for better generalizability of the 
findings based on current mesh use.
Limitations of the study include the retrospective design, which cannot account for recall 
and selection bias. However, the use of validated instruments minimizes the bias regarding 
current prevalence and nature of pain. In addition, although the index surgery occurred in the 
past, pain and health outcomes were measured based on current symptomatology. This limits 
our ability to measure change in pain from baseline, although women with baseline chronic 
pelvic pain were excluded. Another limitation is the high number of patients who could not 
be reached. Although we cannot draw any conclusions about this group, a post-hoc analysis 
showed were no differences in the types of surgeries performed in this group compared with 
the responder group. Although both groups had a mean age in the postmenopausal range, the 
nonresponders were slightly younger at 58.7 years compared with 62.1 years for the 
responders (p = .003). There were no other demographic differences between groups. 
Another limitation is the variety in location of mesh implants used. Whereas stratified 
analysis showed no difference in the rate of pain based on mesh type, this could be due to 
lack of power, as this was not the main objective of the study. Based on this study, clinical 
factors were more likely to affect the development of chronic pain rather than mesh location. 
However, larger studies powered for mesh location are needed to further assess this.
In summary, mesh augmentation improves the strength of pelvic floor repair but is 
accompanied by certain risks that must be balanced against these benefits. The ideal mesh 
material should be durable, noninflammatory, chemically inert, and demonstrate better in 
vivo performance than native tissue. That ideal material has not yet been developed. In the 
meantime, surgeons and patients will need to maintain vigilance when opting to supplement 
surgical repair with mesh and weigh the risks and benefits of each mesh-augmented 
procedure on an individual level based on patient characteristics. Our findings regarding the 
quality and nature of pain at least 1 year after pelvic mesh implant surgery may help aid 
surgeons and patients when considering mesh implant surgery for the treatment of POP and 
SUI.
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Fig. 
Type of pain based on mesh location.
Geller et al. Page 11
J Minim Invasive Gynecol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Geller et al. Page 12
Table 1
Clinical and surgical characteristics for all subjects, women reporting current pelvic pain, and women not 
reporting current pelvic pain at least 1 year after mesh implant surgery
Demographic
All subjects
(n = 160)
Current pain
(n = 24)
No current pain
(n = 136) p
Age, yr 62.1 ± 11.2 57.2 ± 10.6 63.0 ± 11.1 .02*
Body mass index 27.8 ± 5.3 28.8 ± 4.8 27.7 ± 5.4 .36*
Race
 White 150 (94.9) 23 (95.8) 127 (94.8) .99†
 Black 8 (5.1) 1 (4.2) 7 (5.2)
Postmenopausal 138 (90.2) 18 (81.8) 120 (91.6) .23†
Parity 2.3 ± 1.1 2.3 ± .8 2.3 ± 1.2 .81*
Tobacco use (at time of surgery) 3 (1.9) 1 (4.2) 2 (1.5) .39†
 Packs per day .5 ± .0 .0 ± .1 .0 ± .0 .43*
Fibromyalgia 10 (6.5) 5 (21.7) 5 (3.8) .007†
Temporomandibular joint pain 5 (3.2) 0 (.0) 5 (3.8) .99†
Arthritis 41 (26.8) 5 (21.7) 36 (27.7) .55‡
Chronic back pain 13 (8.5) 1 (4.3) 12 (9.2) .69†
Months since surgery 20.8 ± 10.5 19.1 ± 11.0 21.1 ± 10.4 .37*
Number of implants 1.2 ± .4 1.2 ± .4 1.2 ± .4 .40*
Mesh location
 Vaginal prolapse mesh 3 (1.9) 0 (0) 3 (2.2) .11†
 Vaginal SUI sling 90 (56.3) 15 (62.5) 75 (55.1)
 SCP mesh 26 (16.3) 5 (20.8) 21 (15.4)
 Rectal mesh 3 (1.9) 1 (4.2) 2 (1.5)
 SCP mesh and SUI sling 32 (20.0) 1 (4.2) 31 (22.8)
 Vaginal prolapse mesh and SUI sling 6 (3.8) 2 (8.3) 4 (2.9)
Mesh erosion 1 (.6) 0 (0) 1 (.7) .99†
Currently sexually active 75 (46.9) 12 (54.5) 63 (53.8) .95‡
Values are mean ± standard deviation or n (%).
*Student’s t test.
†
Fisher’s exact test.
‡χ2 test.
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Table 2
General health, sexual health, and pain quality scores for women reporting current pelvic pain compared with 
women not reporting current pelvic pain at least 1 year after pelvic mesh implant
Pain questionnaire Current pain
(n = 25)
No current pain
(n = 135)
p
SF-12 Physical 42.4 ± 12.2 49.8 ± 9.6
.002*
SF-12 Mental 51.4 ± 8.6 54.2 ± 9.4
.19*
FSFI (all women) 15.4 ± 11.5 16.4 ± 12.3
.75*
FSFI (sexually
 active only)
23.4 ± 7.7 26.1 ± 7.1
.27*
NPSI† 17.9 ± 12.8 N/A N/A
McGill† 11.6 ± 8.2 N/A N/A
PILL 62.1 ± 28.3 42.8 ± 23.8
.001*
N/A 5 not applicable.
Values are mean ± standard deviation or n (%).
*Student’s t test.
†Only measured in subjects reporting current pain.
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